Literature DB >> 27451086

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

Joseph L Kuti1, Islam M Ghazi1, Richard Quintiliani2, Eric Shore3, David P Nicolau4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27451086     DOI： 10.1016/j.ijantimicag.2016.06.005

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  15 in total

Review 1.  Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

Authors:  Andre Arizpe; Kelly R Reveles; Shrina D Patel; Samuel L Aitken
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

2.  Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.

Authors:  Laura Escolà-Vergé; Carles Pigrau; Ibai Los-Arcos; Ángel Arévalo; Belen Viñado; David Campany; Nieves Larrosa; Xavier Nuvials; Ricard Ferrer; Oscar Len; Benito Almirante
Journal:  Infection       Date:  2018-03-28       Impact factor: 3.553

3.  Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.

Authors:  Marguerite L Monogue; Sean M Stainton; Arlinda Baummer-Carr; Ashley K Shepard; James F Nugent; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

4.  Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model.

Authors:  Veronica Rico Caballero; Safa Almarzoky Abuhussain; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies.

Authors:  Nieves Carbonell; Gerardo Aguilar; Rafael Ferriols; Rotzel Huerta; José Ferreres; Marisa Calabuig; Mar Juan; Carlos Ezquer; Javier Colomina; M Luisa Blasco
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

6.  Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration.

Authors:  Gerardo Aguilar; Rafael Ferriols; Sara Martínez-Castro; Carlos Ezquer; Ernesto Pastor; José A Carbonell; Manuel Alós; David Navarro
Journal:  Crit Care       Date:  2019-04-26       Impact factor: 9.097

Review 7.  Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Infect Dis Ther       Date:  2021-07-18

Review 8.  Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.

Authors:  Luca Gregorio Giaccari; Maria Caterina Pace; Maria Beatrice Passavanti; Francesca Gargano; Caterina Aurilio; Pasquale Sansone
Journal:  Life (Basel)       Date:  2021-05-24

Review 9.  Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.

Authors:  Lu Li; Xin Li; Yanzhe Xia; Yanqi Chu; Haili Zhong; Jia Li; Pei Liang; Yishan Bu; Rui Zhao; Yun Liao; Ping Yang; Xiaoyang Lu; Saiping Jiang
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

10.  A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.

Authors:  Fekade B Sime; Melissa Lassig-Smith; Therese Starr; Janine Stuart; Saurabh Pandey; Suzanne L Parker; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.